Abcam, ab256121, Anti-FCGRT/FCRN antibody [EPR22627-25] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FCGRT/FCRN antibody. Carrier free. Suitable for IP, Flow Cyt, WB, IHC-P and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR22627-25,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, Flow Cyt, IHC-P, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab256121 is the carrier-free version of
ab228975
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein FCGRT also known as FCRN or FcRn has a significant role in the immune system by binding to the Fc region of immunoglobulin G (IgG). This binding prolongs the half-life of IgG by preventing its lysosomal degradation. The molecular mass of the FCGRT protein is roughly 52 kDa. It is prominently expressed in epithelial and endothelial cells across several tissues including the placenta and liver ensuring IgG stability in circulation.
Biological function summary
FCGRT/FCRN is involved in the transportation and recycling of IgG antibodies. It forms a complex with beta-2 microglobulin that contributes to its function. This complex allows IgG antibodies to traverse cellular barriers such as epithelial cells without being digested. This protein is important in maintaining humoral immunity by regulating IgG levels in the bloodstream and similar processes can be observed in mouse FCRN and cynomolgus monkey milk indicating a conserved mechanism across species.
Pathways
FCGRT/FCRN plays a part in the neonatal Fc receptor pathway. This pathway influences IgG homeostasis and impacts antigen presentation to T cells. By doing so it affects immune surveillance and immune tolerance mechanisms. The pathway involves interactions with related proteins such as albumin which also binds to FCRN for extending its half-life in serum.
Disruptions in FCGRT/FCRN functionality relate to autoimmune conditions and inflammatory diseases. Conditions such as lupus and myasthenia gravis show altered IgG recycling or transportation implicating FCRN in their pathology. Accordingly researchers have explored FCRN inhibitors as potential therapeutic interventions. These inhibitors aim to modulate the interaction between FCRN and IgG therefore impacting the disease progression linked to these disorders.